Navigation Links
Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial
Date:6/16/2008

e assessment of the potential relationship between germline and/or tumor DNA sequence alterations and the efficacy of XL184, as well as assessment of pharmacodynamics and pharmacokinetics of XL184. It is expected that approximately 100 sites in 20 countries will participate in this study.

"We are very encouraged by the level of clinical activity in the ongoing XL184 phase 1 study showing a high response rate and durable disease control in medullary thyroid cancer patients, and believe that the FDA-approved phase 3 study design will allow us to rigorously evaluate the clinical benefit of XL184 in this population for which no standard of care is available," said Gisela Schwab, MD, executive vice president and chief medical officer at Exelixis.

The planned initiation of this phase 3 trial is based on encouraging data that were presented earlier this month at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO). Safety and clinical activity data were presented from an ongoing phase 1 trial of XL184 in 69 patients with various solid tumors, including 17 response-evaluable patients with MTC. These data showed a disease control rate (percentage of patients with partial responses or prolonged stable disease >3 months) of 100% in the evaluable MTC patients, with 53% of those patients (9 of 17) experiencing partial responses. The median duration of partial responses and stable disease for patients with MTC has not been reached (range 1+ to 22+ months). Most of the MTC patients in the trial had previously failed other treatments, including tyrosine kinase inhibitors with anti-RET activity (e.g., vandetanib, sorafenib, or motesanib), chemotherapeutic agents, immunotherapy, radioactive iodine, and radiotherapy.

Several additional studies with XL184 have recently been initiated to complement the planned pivotal trial in patients with MTC as part of Exelixis' strategy to rapidly advance compounds into areas of high unmet medical need whi
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Exelixis Announces June 19 Webcast of Presentation at the William Blair 28th Annual Growth Stock Conference
2. Exelixis Receives $150 Million Funding Commitment From Deerfield Management
3. Exelixis Announces June 5 Webcast of Conference Call Regarding Its $150 Million Funding Commitment from Deerfield Management
4. Exelixis Announces June 10 Webcast of Presentation at the Goldman Sachs 29th Annual Global Healthcare Conference
5. REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO
6. Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing
7. Exelixis Announces May 13 Webcast of Presentation at the Bank of America Health Care Conference
8. Exelixis Announces May 6 Webcast of Its First Quarter 2008 Financial Results and Business Update Conference Call
9. Exelixis Announces April 30 Webcast of Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
10. Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting
11. Option to Develop Exelixis Compound Exercised By Genentech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... TeselaGen Biotechnology has received ... expand their bioCAD/CAM software suite, which uses synthetic ... Small Business Innovation Research Phase II grant will be ... license from the Lawrence Berkeley National Laboratory. j5 was ... LBNL laboratory that develops alternative fuel technologies for the ...
(Date:9/30/2014)... . , The researchers ... semiconductor layer. Quantum dots are small structures that spontaneously emit ... laser pulse is fired at the photonic crystal, its refractive ... in the electromagnetic field around it. This change can speed ... dot. As soon as the refractive index recovers its usual ...
(Date:9/30/2014)... 2014 Pacific Northwest Biotechnology, LLC - ... Global Markets Direct,s, ,Pacific Northwest Biotechnology, LLC - ... of the Pacific Northwest Biotechnology, LLC,s pharmaceutical research ... information on the current therapeutic developmental pipeline of ... at various stages, therapeutics assessment by drug target, ...
(Date:9/30/2014)... September 30, 2014 Over the last ... due to rising R&D budgets and increased acceptance of ... growing pharmaceutical and biotechnology industries are also catalyzing the ... filtration market is expected to grow at a strong ... estimated to be worth $2,532.6 million by 2019. The ...
Breaking Biology Technology:TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Ultrafast remote switching of light emission 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5
... Emphysema and chronic bronchitis patients to benefit from rapid, ... ... formoterol fumarate -, NAPA, Calif., Oct. ... MYL ), today announced the launch of Perforomist(TM),(formoterol fumarate) Inhalation ...
... Stem Cell Treatment Hospital ... Hope Not Found at Home, BEIJING, Oct. ... center for effective treatment of Parkinson,s,disease using adult ... more,international patients returned home from China with a ...
... Debiopharm Group,(Debiopharm), a global independent biopharmaceutical development ... Professors Minoru,Toyota and Keiichi Nakayama with the ... work. The Awards were presented during the,General ... the JCA in Yokohama,Japan, by Professor Setsuo ...
Cached Biology Technology:Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 2Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 3Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 4Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 5Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 6American and European Parkinson's Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot 2American and European Parkinson's Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot 3American and European Parkinson's Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot 4Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award 2
(Date:9/30/2014)... This news release is available in German . ... differ in their behavioural response to risky situations such ... Institute for Ornithology now found in a long-term study ... correlates with both metabolic rate and ambient temperature. High ... risk-taking behaviour, as in these scenarios birds were more ...
(Date:9/30/2014)... HONG KONG , Sept. 30, 2014 Winners of ... The Economist Events, Innovation Summit scheduled to take place at the ... At the summit, the award winners will share their experiences and ... people who have made a proven innovation over the past decade, ... the night before the summit. It will be the ...
(Date:9/29/2014)... DC Monday, September 29: Between 1970 and ... fish around the globe dropped 52 percent, says ... World Wildlife Fund (WWF). This biodiversity loss occurs ... resource use of high-income countries. , In addition ... report,s data point to other warning signs about ...
Breaking Biology News(10 mins):Risky metabolism 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7Half of global wildlife lost, says new WWF report 2
... in imaging technology using a combination of light and ... details inside the body. Access to this level of ... but it also has the potential to help health ... symptoms arise. Details describing this advance are published online ...
... Mich. Late-preterm babies those born between 34 and ... and emotional problems, regardless of maternal IQ or demographics, according ... the current edition of the journal Pediatrics . ... have been associated with such problems before, the study represents ...
... more than 60 guides and anglers in the Florida Keys ... assisting in the annual bonefish census. This year,s count, held ... 25-percent from an 8-year mean estimate of 316,805 bonefish to ... Jerry Ault, a fisheries scientist with the University of Miami,s ...
Cached Biology News:Medical imaging breakthrough uses light and sound to see microscopic details inside our bodies 2Late-preterm babies at greater risk for problems later in childhood 2Fall bonefish census sounds warning bell that warrants careful future monitoring 2
Plasmid expressing the LacZ reporter gene....
Puromycin resistance gene (pac), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... for stabilizing 400g of purified RNA samples., ... the stabilization of aqueous RNA samples that ... as guanidine, phenol/chloroform, silica, oligo dT etc ... contain all the necessary components for the ...
... The FRT-PGK-gb2-neo-FRT-loxP template is designed ... eukaryotic cells, respectively. It combines a ... resistance in E.coli with a ... resistance in mammalian cells. The prokaryotic ...
Biology Products: